Background {#Sec1}
==========

Ventilator-associated pneumonia (VAP), one form of hospital-associated pneumonia (HAP), is defined as pneumonia developing in a mechanically ventilated patient ≥ 48 h after tracheal intubation. When it occurs, VAP has been recognized as the leading cause of mortality among patients with nosocomial infections, and VAP patients are hospitalized on average for an additional 4--13 days with excess hospital costs \[[@CR1]\]. Effective antimicrobial therapy requires adequate drug concentrations at the infection site. However, intravenous therapy has altered the pharmacokinetics and poor lung tissue penetration of many antimicrobial agents \[[@CR2]\]. Thus, aerosolized antibiotic therapy directly targets airway and lung parenchyma resulting in high local concentrations and potentially higher clinical responses. Moreover, aerosolized antibiotic therapy, which directly treats lung infections, can be used to decrease systemic antibiotic doses to minimize antibiotic-associated toxicities \[[@CR3]\].

Two previous meta-analyses reported that aerosolized antibiotic therapy might be beneficial in the treatment of VAP \[[@CR4], [@CR5]\]. However, all of these studies were traditional pairwise meta-analyses comparing aerosolized antibiotics with intravenous antibiotics, and none made comparisons between the aerosolized antibiotics. A network meta-analysis (NMA), also known as mixed treatment comparison or multiple treatment comparison, is a method for concurrent comparison of multiple treatments in a single meta-analysis \[[@CR6]\].

In the present study, our objective was to update the evidence to systematically evaluate the effect of aerosolized antibiotics in VAP patients on clinical recovery, microbiological eradication, mortality, and nephrotoxicity; we also used an NMA approach which enabled us to assess three aerosolized antibiotics by indirect comparison to determine their efficacy.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

We included the studies from two systematic reviews \[[@CR4], [@CR5]\]. In addition, we also searched the PubMed, EMBASE, and Cochrane databases from inception to September 2017 to identify potentially relevant studies. Search terms included several parameters: 1) ventilator associated pneumonia OR VAP OR respiratory infection OR respiratory tract OR hospital acquired pneumonia OR nosocomial pneumonia; 2) aerolised OR aerosolized OR inhaled OR nebulised OR nebulized. We also evaluated the reference lists of the relevant clinical trials to identify additional studies.

Studies were included if they met several criteria: 1) patients in a study population that were mechanically ventilated and diagnosed with VAP; 2) intervention which included the use of inhaled antibiotics for treatment of VAP compared with intravenous antibiotics; and 3) at least one of the following outcomes was reported: clinical recovery, microbiological eradication, mortality, and nephrotoxicity.

Study quality assessment {#Sec4}
------------------------

The Newcastle-Ottawa scale (NOS) for observational studies was used to assess the quality of the included studies. The NOS statement was judged on three broad perspectives (selection, comparability, and outcome) consisting of eight items. The qualities of randomized clinical trials were assessed using the risk of bias tool recommended by the Cochrane Collaboration. We assigned a value of high, unclear, or low to several parameters: 1) random sequence generation; 2) allocation concealment; 3) blinding of participants and personnel; 4) blinding of outcome assessment; 5) incomplete outcome data; 6) selective reporting; and/or 7) other bias.

Statistical analysis {#Sec5}
--------------------

We used the STATA program (Stata Corporation, College Station, Texas) for pairwise meta-analysis. The differences between the two groups were calculated as the relative risk (RR) and 95% confidence interval (CI) for dichotomous outcomes. Heterogeneity was assessed by the Cochran *Q* statistic and the *I*^2^ statistic. A *P* value ≤ 0.10 together with an *I*^2^ value ≥ 50% indicates significant heterogeneity. *I*^2^ values ≤ 50% represented acceptable between-study heterogeneity, and the fixed-effects model was selected. Otherwise, the random-effects model was selected \[[@CR7], [@CR8]\]. Publication bias was determined using the funnel plot and assessed by Egger's test. We performed the NMA within a Bayesian framework using JAGS (version 4.2.0), R software (version 3.4.4), and the rjags and gemtc packages. The probability that each aerosolized antibiotic therapy was the best among the given treatments was determined by evaluating the rank probabilities. A higher probability of achieving rank 1 indicated a higher probability of being the best. We used these results for our interpretation.

Results {#Sec6}
=======

Selection and characteristics of the studies {#Sec7}
--------------------------------------------

We identified 13 studies through the reanalysis of the two systematic reviews, and four studies through the PubMed, EMBASE, and Cochrane search. These trials were published between 2000 and 2017. Accordingly, the current meta-analysis included 17 studies \[[@CR9]--[@CR25]\]. The detailed steps of the study selection process are shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Study flow diagram

Table [1](#Tab1){ref-type="table"} shows the major characteristics of the included trials. There were nine observational studies and eight randomized clinical trials. Fifteen studies presented the outcome of clinical recovery \[[@CR9]--[@CR21], [@CR23], [@CR24]\], and 10 presented the outcome of microbiological eradication \[[@CR9], [@CR10], [@CR12]--[@CR15], [@CR19]--[@CR22]\]. Mortality was reported in 14 trials \[[@CR10], [@CR11], [@CR13]--[@CR17], [@CR19]--[@CR25]\], and nephrotoxicity was reported in six trials \[[@CR10], [@CR13], [@CR15], [@CR18], [@CR19], [@CR21]\]. For the network meta-analysis, we excluded studies that used several inhaled antibiotics \[[@CR9], [@CR22], [@CR25]\]. Three studies investigated the effect of inhaled amikacin \[[@CR20], [@CR21], [@CR24]\], three studies concerned inhaled tobramycin \[[@CR16]--[@CR18]\], and eight studies concerned colistin \[[@CR10]--[@CR15], [@CR19], [@CR23]\].Table 1Characteristics of studies included in the meta-analysisStudy, yearCountryInclusion populationNo. of patientsDisease severityRespiratory comorbiditiesAdministration strategyAntibiotic given (dose)Device for drug deliveryMain outcomesQuality assessment/Cochrane risk of bias^a^(AS/IV)ASIVASIVASIVObservational studies Ghannam, 2009 \[[@CR9]\]USAGram-negative bacteria VAP16/16CPIS score: 7 ± 2.9CPIS score: 6 ± 1.8COPD: 3COPD: 6Substitution strategyColistin (100 mg every 8 h), tobramycin (300 mg b.i.d), gentamicin (100 mg t.i.d), and amikacin (100 mg t.i.d. or 300 mg b.i.d)Amikacin (100 mg per 3 ml), gentamicin (40 mg per ml), and colistin (75 mg per 4 ml)Jet nebulizerClinical recovery, microbiological eradication9 Kofteridis, 2010 \[[@CR10]\]GreeceMDR VAP due to Gram-negative bacteria43/43APACHE II score: 16.95 ± 6.59APACHE II score: 17.74 ± 7.61COPD: 12COPD: 7Adjunctive strategyColistin (2 million IU b.i.d)Colistin (3 million IU t.i.d)Not describedClinical recovery, microbiological eradication, all-cause mortality, nephrotoxicity9 Korbila, 2010 \[[@CR11]\]GreeceMicrobiologically documented VAP78/43APACHE II score: 17.4 ± 6APACHE II score: 19.2 ± 7Pulmonary: 17Pulmonary: 9Adjunctive strategyColistin (1 million IU)Colistin (6.4 ± 2.3 million)Ultrasonic nebulizerClinical recovery, mortality9 Pérez-Pedrero, 2011 \[[@CR12]\]SpainVAP due to multi-resistant *Acinetobacter baumannii*36/18APACHE II score: 11.2 ± 4.3APACHE II score: 12.8 ± 5.7Not describedNot describedAdjunctive strategyColistin (1 million every 8 h, 0.5 million every 8 h, or 1 million b.i.d)Colistin (1 million every 8 h, 0.5 million every 8 h, or 1 million b.i.d)Not describedClinical recovery, microbiological eradication8 Kalin, 2012 \[[@CR13]\]TurkeyVAP due to multi-resistant *A. baumannii*15/29APACHE II score: 22APACHE II score: 22COPD: 4COPD: 6Adjunctive strategyColistin (150 mg b.i.d)Colistin (2.5 mg/kg b.i.d or every 6 h)Not describedClinical recovery, microbiological eradication, all-cause mortality, nephrotoxicity9 Arnold, 2012 \[[@CR25]\]USA*Pseudomonas aeruginosa* and *A. baumannii* VAP19/74APACHE II score: 17.5 ± 5.3APACHE II score: 21.4 ± 5.7Pulmonary: 22Pulmonary: 6Adjunctive strategyColistin (150 mg b.i.d) or tobramycin (300 mg b.i.d)Standard IV antibioticsNot describedAll-cause mortality8 Doshi, 2013 \[[@CR14]\]USAMDR VAP due to Gram-negative bacteria44/51APACHE II score: 22.4 ± 7.1APACHE II score: 24 ± 6.9Not describedNot describedAdjunctive strategyColistin (75--150 mg b.i.d)Colistin (2.5 mg/kg b.i.d)Jet or vibrating mesh nebulizerClinical recovery, microbiological eradication, hospital mortality7 Tumbarello, 2013 \[[@CR15]\]ItalyPatients with VAP caused by *Acinetobacter*, *Pseudomonas*, or *Klebsiella*104/104CPIS: 7.8 ± 1.2CPIS: 7.9 ± 1.3COPD: 21COPD: 28Adjunctive strategyColistin (1 million IU t.i.d)Colistin (0.1 IU/kg every 8 to 12 h)Jet or ultrasonic nebulizerClinical recovery, microbiological eradication, all-cause mortality, nephrotoxicity9 Migiyama, 2017 \[[@CR16]\]JapanARDS patients with VAP caused by *P. aeruginosa*22/22APACHE II score: 26.2 ± 6.6APACHE II score: 24.5 ± 7.0Pulmonary: 6Pulmonary: 5Adjunctive strategyTobramycin (240 mg)TobramycinUltrasonic nebulizerClinical recovery, ICU mortality9 Le Conte, 2000 \[[@CR17]\]FranceIntubated and mechanically ventilated patients with nosocomial pneumonia21/17N/AN/ANot describedNot describedAdjunctive strategyTobramycin (6 mg/kg/day)Betalactam and tobramycinPneumatic nebulizerClinical recovery, mortalityHigh Hallal, 2007 \[[@CR18]\]USAVAP caused by *Pseudomonas* or *Acinetobacter*5/5APACHE II score: 17 ± 1.26APACHE II score: 15 ± 3.3Not describedNot describedSubstitution strategyTobramycin (300 mg b.i.d)Betalactam and tobramycinJet nebulizerClinical recovery, nephrotoxicityHigh Rattanaumpawan, 2010 \[[@CR19]\]ThailandGram-negative bacteria VAP51/49APACHE II score: 19.1 ± 5.8APACHE II score: 18.5 ± 4.7Not describedNot describedAdjunctive strategyColistin (75 mg b.i.d)Standard intravenous antibioticsJet or ultrasonic nebulizerClinical recovery, microbiological eradication, 28-day mortality, nephrotoxicityHigh Lu, 2011 \[[@CR20]\]FranceVAP caused by *Pseudomonas*20/20CPIS score: 8 (7--8)CPIS score: 9 (8--9)COPD: 3COPD: 4Substitution strategyAmikacin (25 mg/kg/day)Amikacin (15 mg/kg/day) and ceftazidime (90 mg/kg/3 h)Vibrating nebulizerClinical recovery, microbiological eradication, 28-day mortalityHigh Niederman, 2012 \[[@CR21]\]France/Spain/USAMechanically ventilated patients with Gram-negative pneumonia46/22CPIS score: 6.8 (1.2)CPIS score: 7 (1.2)Not describedNot describedAdjunctive strategyAmikacin (400 mg b.i.d or 400 mg/day)Standard intravenous antibioticsVibrating mesh nebulizerClinical recovery, microbiological eradication, all-cause mortality, nephrotoxicityLow Palmer, 2014 \[[@CR22]\]USAPatients with high risk for MDR organisms in the respiratory tract24/18APACHE II score: 20.96 ± 5.8APACHE II score: 14.4 ± 5.5COPD: 3COPD: 2Adjunctive strategyVancomycin (120 mg t.i.d), gentamicin sulfate (80 mg t.i.d), or amikacin (400 mg t.i.d)Standard IV antibioticsJet nebulizerMicrobiological eradication, all-cause mortalityHigh Abdellatif, 2016 \[[@CR23]\]TunisiaGram-negative bacteria VAP73/76SOFA score: 7.03 ± 3.8SOFA score: 6.5 ± 4.1Pulmonary: 32Pulmonary: 29Adjunctive strategyColistin (4 million IU t.i.d)Imipenem (1 g t.i.d)Ultrasonic vibrating plate nebulizerClinical recovery, 28-day mortalityLow Kollef, 2017 \[[@CR24]\]USAGram-negative bacteria VAP71/72APACHE II score: 18.5 ± 5.6APACHE II score: 18.4 ± 5.9Not describedNot describedAdjunctive strategyAmikacin (300 mg) and fosfomycin (120 mg)Meropenem or imipenemVibrating plate electronic nebulizerClinical recovery, 28-day mortalityLow*APACHE* Acute Physiology and Chronic Health Evaluation, *AS* aerosolized, *b.i.d.* twice daily, *COPD* chronic obstructive pulmonary disease, *CPIS* Clinical Pulmonary Infection Score, *ICU* intensive care unit, *IU* international units, *IV* intravenous, *MDR* multidrug resistant, *N/A* indicates not available, *SOFA* Sequential Organ Failure Assessment, , *t.i.d.* three times daily, *VAP* ventilator-associated pneumonia^a^Quality assessment is shown for observational studies, and Cochrane risk of bias is shown for randomized controlled trials

Pairwise meta-analysis {#Sec8}
----------------------

The overall pooled RR of clinical recovery, microbiological eradication, mortality, and nephrotoxicity are shown in Additional file [1](#MOESM1){ref-type="media"}: Figure S1. Additional file [1](#MOESM1){ref-type="media"}: Figure S1A shows the estimates of clinical recovery rates from fifteen studies. Aerosolized antibiotics were associated with significantly higher rates of clinical recovery (RR 1.21, 95% CI 1.09--1.34; *P* = 0.001). There was no statistical heterogeneity in the fixed effect model (*I*^2^ = 36.2%).

Ten trials reported microbiological eradication as an outcome, and the pooled results indicated that aerosolized antibiotics also had a beneficial effect (RR 1.42, 95% CI 1.22--1.65; *P* \< 0.0001), despite significant heterogeneity among the studies (*I*^2^ = 68.5%) (Additional file [1](#MOESM1){ref-type="media"}: Figure S1B).

Mortality at the longest follow-up was available in 14 studies; aerosolized antibiotics had similar effects to control groups (RR 0.88, 95% CI 0.74--1.04; *P* = 0.127) with no evidence of statistical heterogeneity (*I*^2^ = 23.6%) (Additional file [1](#MOESM1){ref-type="media"}: Figure S1C).

Six studies presented data regarding complications on nephrotoxicity; aerosolized antibiotics were not associated with an increased risk of nephrotoxicity (RR 1.00, 95% CI 0.72--1.39; *P* = 0.995) with no evidence of statistical heterogeneity (*I*^2^ = 19.4%) (Additional file [1](#MOESM1){ref-type="media"}: Figure S1D).

Publication bias {#Sec9}
----------------

We detected no evidence of publication bias after assessing funnel plots (Additional file [2](#MOESM2){ref-type="media"}: Figure S2) and Egger's test (clinical recovery *P* = 0.553, microbiological eradication *P* = 0.156, mortality *P* = 0.869 and nephrotoxicity *P* = 0.223). The data suggested that there was no evidence of publication bias for clinical recovery, microbiological eradication, mortality and/or nephrotoxicity.

Sensitivity analyses {#Sec10}
--------------------

Sensitivity analyses were carried out to determine the influence of each study on the pooled RR, and the statistical findings were not materially altered by the elimination of any study (Additional file [3](#MOESM3){ref-type="media"}: Figure S3).

Bayesian network meta-analysis {#Sec11}
------------------------------

There were no trials comparing outcomes among the aerosolized antibiotics, and all trials had an intravenous antibiotics arm. Thus, we pooled direct comparisons to obtain indirect comparisons by comparing aerosolized tobramycin versus aerosolized colistin, aerosolized tobramycin versus aerosolized amikacin, and aerosolized colistin versus aerosolized amikacin. In individual comparisons for clinical recovery using intravenous antibiotics as the reference, aerosolized tobramycin and colistin were more likely to increase the rate of clinical recovery (NMA: RR 1.7, 95% CI 1.1--2.7; and RR 1.2, 95% CI 1.0--1.4, respectively; Fig. [2a](#Fig2){ref-type="fig"}). Aerosolized tobramycin was associated with a significantly higher rate of clinical recovery compared with aerosolized amikacin (NMA: RR 1.8, 95% CI 1.1--3.0; Fig. [2a](#Fig2){ref-type="fig"}). There were no significant differences among the other comparisons of the network meta-analysis for clinical recovery (Fig. [2](#Fig2){ref-type="fig"}). The assessment of rank probabilities indicated that tobramycin (92.3% probability) presented the greatest likelihood of improving efficacy among the evaluated aerosolized antibiotics for treating VAP, followed by colistin (SUCRA 7.4% probability) and then amikacin (0.2% probability) (Fig. [2b](#Fig2){ref-type="fig"}). We conducted subgroup analyses according to geography, type of inhaled drug delivery system, VAP with or without multidrug resistance (MDR), type of studies, and administration strategy (Table [2](#Tab2){ref-type="table"}). Results of our subgroup analyses from rank probabilities suggested that tobramycin displayed the best benefit for clinical recovery, followed by colistin, and then amikacin.Fig. 2**a** Network estimates among aerosolized antibiotics for clinical recovery. **b** Rank probabilities among aerosolized antibiotics for clinical recovery based on the network meta-analysis. The number of patients in each antibiotic arm: control, 476; amikacin, 135; colistin, 372; and tobramycin, 48. CI confidence intervalTable 2Results of subgroup analysisOutcomeSubgroupRelative risk (95% confidence interval) and rank probabilitiesTobramycin vs control; tobramycin (rank probability)Colistin vs control; colistin (rank probability)Amikacin vs control; amikacin (rank probability)Tobramycin vs colistinTobramycin vs amikacinColistin vs amikacinClinical recoveryGeography USA2.37 (1.7--5.62); tobramycin 97.3%1.3 (0.68--2.7); colistin 2.2%0.68 (0.27--1.7); amikacin 0.2%1.83 (1.2--4.67)3.4 (2.2--8.89)2 (0.65--6.3) Europe1.52 (0.52--6.6); tobramycin 65.4%1.2 (0.86--1.5); colistin 28.7%0.98 (0.67--1.5); amikacin 4.6%1.3 (0.42--5.7)1.6 (0.5--7.1)1.3 (0.72--1.9) Asia1.6 (0.74--3.3); tobramycin 82.3%0.95 (0.48--1.9); colistin 5.6%--1.6 (0.60--4.5)----Type of inhaled drug delivery system Jet nebulizer2.1 (1.5--5.34); tobramycin 98.6%1.1 (0.71--1.8); colistin 1.2%--2.53 (1.2--6.7)---- Ultrasonic nebulizer1.5 (0.85--3); tobramycin 78.8%1.2 (0.95--1.6); colistin 20.5%--1.3 (0.67--2.6)---- Vibrating nebulizer--1.3 (0.93--2); colistin 91.9%0.95 (0.72--1.2); amikacin 4.2%----1.4 (0.91--2.3)VAP with or without MDR VAP with MDR--1.2 (0.70--1.7); colistin 66.4%0.97 (0.40--2.5); amikacin 24.8%----1.2 (0.40--3.1) VAP without MDR1.7 (1.1--3.2); tobramycin 88.5%1.2 (0.83--1.7); colistin 9%0.68 (0.27--1.6); amikacin 2.1%1.5 (0.8--2.9)2.6 (0.94--7.8)1.8 (0.68--4.8)Type of studies Randomized controlled trials2.2 (0.95--8); tobramycin 92.9%1.1 (0.71--1.8); colistin 5.6%0.94 (0.65--1.3); amikacin 0.8%2.5 (0.93--9.9)2.4 (0.96--8.7)1.2 (0.69--2.1) High risk of bias2.2 (0.91--7.7); tobramycin 87.5%0.94 (0.43--2); colistin 5.6%0.98 (0.47--2.1); amikacin 5.7%2.4 (0.74--10)2.3 (0.73--9.5)0.96 (0.33--2.8) Low risk of bias--1.4 (0.73--2.8); colistin 82.1%0.92 (0.59--1.3); amikacin 7.7%----1.5 (0.72--3.5) Observational studies1.6 (0.78--3.3); tobramycin 75.9%1.2 (0.88--1.6); colistin 22.9%--1.3 (0.63--2.9)---- NOS = 91.6 (0.48--5.1); tobramycin 70.8%0.96 (0.51--1.81); colistin 23.7%--1.3 (0.40--5.5)---- NOS \< 9--1.2 (0.84--1.9); colistin 87.6%--------Administration strategy Adjunctive strategy1.6 (0.94--2.70); tobramycin 81.4%1.2 (1.0--1.4); colistin 16.8%0.93 (0.64--1.3); amikacin 1.4%1.3 (0.76--2.3)1.7 (0.92--3.2)1.3 (0.87--2) Substitution strategy1.57 (0.46--5.34); tobramycin 98.9%--0.96 (0.76--1.21); amikacin 0.7%--1.64 (0.47--5.69)--MortalityGeography USA--1.4 (0.76--2.6); colistin 3.6%0.66 (0.30--1.4); amikacin 83.9%----2.1 (0.79--5.8) Europe0.31 (0.039--1.6); tobramycin 85.7%1.2 (0.40--4.1); colistin 0.1%0.87 (0.57--1.3); amikacin 7.8%0.36 (0.044--5.0)0.25 (0.022--1.8)0.72 (0.20--2.3) Asia0.33 (0.074--1.4); tobramycin 86.9%0.92 (0.26--3.3); colistin 10.6%--0.36 (0.051--2.4)----Type of inhaled drug delivery system Jet nebulizer--0.88 (0.63--1.2); colistin 81.6%-------- Ultrasonic nebulizer0.33 (0.11--0.87); tobramycin 97.2%0.92 (0.64--1.4); colistin 1.7%--0.36 (0.11--1.0)---- Vibrating nebulizer--1.3 (0.70--2.4); colistin 20%1.3 (0.68--2.6); amikacin 14.8%----1.0 (0.40--2.4)VAP with or without MDR VAP with MDR--0.81 (0.55--1.2); colistin 70.9%1.3 (0.39--6.3); amikacin 22.3%----0.61 (0.12--2.1) VAP without MDR0.34 (0.13--0.78); tobramycin 71.7%0.91 (0.54--1.5); colistin 7.4%0.7 (0.3--1.7); amikacin 26.7%0.37 (0.12--1)0.48 (0.13--1.6)1.3 (0.47--3.5)Type of studies Randomized controlled trials0.31 (0.039--1.6); tobramycin 80.9%0.95 (0.45--2); colistin 6.6%0.83 (0.41--1.8); amikacin 11.3%0.32 (0.036--2)1.1 (0.38--3.1)0.37 (0.042--2.3) High risk of bias0.31 (0.039--1.8); tobramycin 73.5%0.92 (0.32--2.7); colistin 8%1.1 (0.11--10); amikacin 16.3%0.33 (0.033--2.7)0.28 (0.013--5.2)0.86 (0.073--10) Low risk of bias--0.81 (0.43--1.6); colistin 31.4%1 (0.25--3.9); amikacin 50.3%----1.2 (0.27--5.5) Observational studies0.34 (0.11--0.9); tobramycin 95.7%0.83 (0.58--1.1); colistin 3.9%--0.41 (0.12--1.2)---- NOS = 90.34 (0.094--0.96); tobramycin 95.1%0.86 (0.54--1.3); colistin 4.2%--0.39 (0.1--1.2)---- NOS \< 9--0.67 (0.35--1.3); colistin 90.2%--------Administration strategy Adjunctive strategy0.34 (0.14--0.72); tobramycin 95%0.85 (0.66--1.1); colistin 0.83%0.8 (0.44--1.5); amikacin 4.1%0.4 (0.16--0.88)0.42 (0.14--1.1)1.1 (0.54--2) Substitution strategy----0.99 (0.088--9.5); amikacin 48.7%------*MDR* multidrug resistance, *NOS* Newcastle-Ottawa scale, *VAP* ventilator-associated pneumonia

None of the studies used aerosolized tobramycin to evaluate the effects on microbiological eradication. Aerosolized colistin had a higher rate of microbiological eradication when compared with intravenous antibiotics (NMA: RR 1.3, 95% CI 1.0--1.6; Fig. [3a](#Fig3){ref-type="fig"}). There were no significant differences among the other comparisons of the network meta-analysis for microbiological eradication (Fig. [3a](#Fig3){ref-type="fig"}). Ranking analysis revealed that colistin presented the highest rate of microbiological eradication (86.2% probability) (Fig. [3b](#Fig3){ref-type="fig"}).Fig. 3**a** Network estimates among aerosolized antibiotics for microbiological eradication. **b** Rank probabilities among aerosolized antibiotics for microbiological eradication based on the network meta-analysis. The number of patients in each antibiotic arm: control, 271; amikacin, 74; and colistin, 241. CI confidence interval

Taking intravenous antibiotics as the reference revealed no statistically significant differences in mortality in aerosolized amikacin and colistin, but aerosolized tobramycin showed lower mortality risk (NMA: RR 0.34, 95% CI 0.14--0.70) (Fig. [4a](#Fig4){ref-type="fig"}). Aerosolized tobramycin was also associated with significantly lower mortality compared with aerosolized amikacin (NMA: RR 0.26, 95% CI 0.089--0.67) and aerosolized colistin (NMA: RR 0.39, 95% CI 0.16--0.84) (Fig. [4a](#Fig4){ref-type="fig"}). Ranking analysis revealed that the hierarchy for efficacy in avoiding death (highest to lowest rank) was tobramycin (98.5% probability), followed by colistin (0.99% probability) and then amikacin (0.37% probability) (Fig. [4b](#Fig4){ref-type="fig"}). Table [2](#Tab2){ref-type="table"} shows the rank probabilities of subgroup analyses that provided the hierarchies for the mortality of the aerosolized antibiotics. Ranking analysis revealed that tobramycin was the best treatment in terms of reducing hospital mortality.Fig. 4**a** Network estimates among aerosolized antibiotics for mortality. **b** Rank probabilities among aerosolized antibiotics for mortality based on the network meta-analysis. The number of patients in each antibiotic arm: control, 464; amikacin, 138; colistin, 362; and tobramycin, 43. CI confidence interval

The forest plot for the risk of nephrotoxicity is shown in Fig. [5a](#Fig5){ref-type="fig"}. There were no significant differences among any comparisons of the network meta-analysis (Fig. [5a](#Fig5){ref-type="fig"}). Ranking analysis revealed that the hierarchy for safety in avoiding renal toxicity (highest to lowest rank) was tobramycin (69.4% probability), followed by amikacin (29.4% probability) and then colistin (0.5% probability) (Fig. [5b](#Fig5){ref-type="fig"}).Fig. 5**a** Network estimates among aerosolized antibiotics for nephrotoxicity. **b** Rank probabilities among aerosolized antibiotics for nephrotoxicity based on the network meta-analysis. The number of patients in each antibiotic arm: control, 231; amikacin, 45; colistin, 5; and tobramycin, 230. CI confidence interval

Discussion {#Sec12}
==========

Previous studies have demonstrated that aerosolized antibiotics affected the clinical prognosis in VAP treatment. Whether aerosolized antibiotics are beneficial or harmful for critically ill patients has long been a matter of debate. In this meta-analysis, we found that aerosolized antibiotics could improve clinical recovery and microbiological eradication. In addition, there were no differences in terms of outcomes such as mortality or nephrotoxicity. The present network meta-analysis and ranking analysis suggest that the probability of being the best aerosolized therapy for VAP was tobramycin with respect to clinical recovery and mortality, and colistin for microbiological eradication. Although this was a hypothesis-generating study, the current study is the first network meta-analysis to compare different aerosolized antibiotics in the treatment of VAP. The present meta-analysis is different from the two previous ones \[[@CR4], [@CR5]\]. We have updated the studies for this analysis, separately compared each aerosolized antibiotic with intravenous therapy, assessed the quality of evidence, detected publication bias, and conducted sensitivity analyses. A previous meta-analysis by Zampieri et al. investigated the role of aerosolized antibiotics in VAP treatment \[[@CR4]\]. This analysis found the same benefits as our analysis on clinical recovery, mortality, and nephrotoxicity, but aerosolized antibiotics did not increase the rate for microbiological eradication. Contrary to their microbiological eradication findings, our analysis indicated that aerosolized antibiotics also have a beneficial effect. Thus, there may have been an inadequate sample size to correct the type II error in the study of Zampieri et al. In addition, we used network meta-analysis to identify an optimal aerosolized antibiotic for VAP.

VAP remains an important infectious complication of mechanical ventilation and is commonly due to MDR pathogens (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *P. aeruginosa*, and enterobacter spp.). Because of MDR pathogens, the capability of commonly used intravenous antibiotics to cross the lung parenchyma is significantly inhibited \[[@CR26], [@CR27]\]. Inadequate concentrations of intravenous antibiotics may result in failure to reach inhibitory concentrations. Aerosolized antibiotics may be a useful treatment since aerosolization directly targets the airways and localizes the drug to the pulmonary parenchyma, thus bypassing the poor lung penetration of many antibiotics. Aerosolized antibiotics therefore make it possible to achieve high local antibiotic concentrations relative to an organism's minimum inhibitory concentration while concurrently minimizing systemic toxicities by concentrating antibiotics in the lungs rather than spreading them throughout the body \[[@CR28]\].

The appropriate aerosolized antibiotic remains a matter of controversy, and the most studied are colistin and aminoglycosides. The selection of the aerosolized antibiotic should encompass several properties and characteristics to achieve maximum effectiveness including: 1) activity against the causative pathogen; 2) physical properties to ensure maximal pulmonary delivery and minimal extrapulmonary loss; and 3) the achievement of adequate concentrations in the lung well above the pathogen's minimum inhibitory concentration, taking into account the need for the prevention of resistance and the presence of biofilm \[[@CR29]\].

In the presence of severe experimental lung infection, aminoglycoside plasma concentrations were found in the same range after nebulization and intravenous administration \[[@CR30]\]. Furthermore, inhaled aminoglycosides prevent growth of bacterial biofilms \[[@CR31]\]. Inhaled tobramycin has a wide range of activity against Gram-negative organisms, including *P. aeruginosa*. Tobramycin is also preferable for inhaled use because of moderately lipophilic and positively charged small molecules \[[@CR27]\]. Amikacin is another aminoglycoside. The low bioavailability of nebulized amikacin may result in administration of high dosesand hence potentially increase systemic toxicities. Mohr et al. reported that pharmacokinetic properties and dosing strategies were better defined for inhaled tobramycin than for inhaled amikacin \[[@CR32]\]. Studies in animals have shown that aerosolized colistin has a limited systemic diffusion in pneumonia \[[@CR33]\]. Likewise, inhaled colistin also has high mucin binding that might lead to insufficient antibiotic effectiveness to kill bacteria \[[@CR34]\]. As a consequence, a dosage exceeding the common dose of colistin treating VAP may enhance the rate of clinical recovery and microbiological eradication but increase the risk of toxicity. Therefore, tobramycin may have more potential effects on clinical recovery and be promising for its effects on mortality and nephrotoxicity.

In seeking to optimize treatment, network meta-analysis was used to gain further insight into the best preferred agent. The present network meta-analysis found that aerosolized tobramycin and colistin (especially tobramycin) were more likely to increase the rate of clinical recovery. Aerosolized tobramycin also had additional benefits on mortality, and aerosolized colistin had a higher rate of microbiological eradication. Amikacin had no significant differences in clinical recovery, microbiological eradication, mortality, or nephrotoxicity compared with intravenous antibiotics. Accordingly, the present network meta-analysis and the clustered ranking plot suggest that tobramycin present the best outcome for clinical recovery and mortality, and colistin present the best outcome for microbiological eradication.

Aerosolized antibiotics seem to be attractive alternatives for VAP treatment. However, an in-vivo randomized controlled trial examining adjuvant therapy with aerosolized antibiotics in VAP with varying degrees of bacterial resistance has shown that aerosolized antibiotics have no effect on the clinical course, including the serial Clinical Pulmonary Infection Score (CPIS), clinical cure rates, ventilator-free and ICU days, or mortality \[[@CR24]\]. Despite the weak evidence in our analysis suggesting that the administration of aerosolized antibiotics such as colistin or tobramycin instead of the administration of intravenous antibiotics might be a good option for the treatment of VAP, there may as yet be no recommendations for using them in standard clinical practice. The rationale for the recommendation of aerosolized antibiotics requires other large multicenter trials to determine if these preliminary findings will result in better clinical activity and decreased microbial resistance in patients with VAP.

Some important limitations of the study should not be overlooked. First, different criteria for clinical recovery, microbiological eradication, and nephrotoxicity in the included trials might affect the robustness of our findings. The endpoint of microbiologic eradication is of uncertain value when measured during the use of inhaled antibiotics since the inhaled antibiotics are in the respiratory sample sent for culture which may influence the accuracy of the endpoint. Second, there are many factors which may impact the effect of inhaled antibiotics including types of nebulizers, ventilator settings, ventilator and circuit connections, and circuit humidification and filtering. We could not obtain sufficient data suggesting that other study design issues should be addressed. Third, the eligible studies had substantial differences in terms of the causative microorganisms, and the impact of inhaled antibiotics might vary against different pathogens. Fourth, a major concern when small studies are included in our analysis is the presence of a "small-study effect", which arises from publication bias and selection bias and results in lower methodological quality \[[@CR35]\]. The small-study effect was present in the analysis of treatment success in VAP patients with respect to aerosolized antibiotics. This should be taken into careful consideration when evaluating the results of the present analysis. Fifth, although network meta-analysis allowed us to compare the efficacy and safety of inhaled antibiotics, we acknowledge the limitation that interpretation of a network meta-analysis relies on the insufficient indirect comparison of outcomes through common comparators. Sixth, we included observational studies and randomized controlled trials; however, observational studies have the risk of overrated pooled estimates.

Conclusions {#Sec13}
===========

Aerosolized antibiotics appear to be useful treatment for VAP with respect to clinical recovery and microbiological eradication, and do not seem to increase mortality or nephrotoxicity risks. Our network meta-analysis in patients with VAP suggests that clinical recovery benefits are associated with aerosolized tobramycin and colistin (especially tobramycin), microbiological eradication with aerosolized colistin, and survival with aerosolized tobramycin, mostly based on observational studies. Moreover, we should take into account that some studies using aerosolized antibiotics failed to show an improvement, and data of other studies are still not published. Due to the low level of evidence, definitive recommendations cannot be made before additional large randomized studies are carried out.

Key messages {#Sec14}
============

Aerosolized antibiotics appear to be beneficial for the treatment of VAP.The current evidence from network meta-analysis indicates that aerosolized tobramycin is associated with the best outcome on clinical recovery and mortality.The current evidence from network meta-analysis indicates that aerosolized colistin is associated with improved clinical recovery and microbiological eradication.
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Additional file 1:**Figure S1.** Forest plots showing the effect of aerosolized antibiotics on (A) clinical recovery, (B) microbiological eradication, (C) mortality, and (D) nephrotoxicity. (TIF 8222 kb) Additional file 2:**Figure S2.** Funnel plots for the rate of (A) clinical recovery, (B) microbiological eradication, (C) mortality, and (D) nephrotoxicity. (TIF 2106 kb) Additional file 3:**Figure S3.** Sensitivity analyses of the included studies reporting aerosolized antibiotics on (A) clinical recovery, (B) microbiological eradication, (C) mortality, and (D) nephrotoxicity. (TIF 4998 kb)
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